Nifty 50
- Max Healthcare₹99547.90 (5.06%)
- Tata Motors PV₹266.20-21.20 (-7.38%)
- ITC₹292.907.90 (2.77%)
- Tata Steel₹183.51-3.17 (-1.70%)
- Bharti Airtel₹2,158.7052.70 (2.50%)
- Adani Enterprises₹2,654-34.00 (-1.26%)
- Asian Paints₹2,600.9050.90 (2.00%)
- Bajaj Finance₹1,103.10-13.90 (-1.24%)
- Apollo Hospitals₹8,690164.00 (1.92%)
- Coal India₹399.50-4.00 (-0.99%)
- Eternal₹370.556.90 (1.90%)
- Hindalco Industries₹934.95-8.65 (-0.92%)
- Tata Consumer ₹1,098.9019.90 (1.84%)
- InterGlobe Aviation₹5,540.80-46.50 (-0.83%)
- Kotak Mahindra Bank₹496.558.00 (1.64%)
- JSW Steel₹1,337-11.00 (-0.82%)
- Nestle₹1,28016.80 (1.33%)
- Bajaj Finserv₹1,851.80-13.20 (-0.71%)
- SBI₹1,093.4013.40 (1.24%)
- Bajaj Auto₹10,801-49.00 (-0.45%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Aurobindo Pharma Posts 32.5% Rise in Q2 Net Profit on Record Revenue
Authored By PTI | Published at: Nov 5, 2026 10:37 AM IST

Open Free Demat Account
New Delhi: Aurobindo Pharma Ltd on Wednesday reported a 32.5 per cent increase in net profit to Rs 1,123.84 crore during the September quarter, driven by growth across key businesses.
The pharma major had posted a profit after tax (PAT) of Rs 848.13 crore during the same period of the previous fiscal.
The company posted its highest-ever quarterly revenue from operations at Rs 10,263 crore, up 24 per cent year-on-year, Aurobindo Pharma said in a regulatory filing.
The company’s expenses also rose to Rs 8,740.9 crore from Rs 7,132.03 crore a year earlier, it said.
Its US revenue increased 25 per cent to Rs 4,555 crore, while the Europe business jumped 27 per cent to Rs 3,161 crore during the quarter under review, the company said in a release.
As of September 30, on a cumulative basis, the company filed 900 Abbreviated New Drug Applications (ANDAs) with the US health regulator and received 747 final approvals and 35 tentative approvals.
In the half year ended September, Aurobindo Pharma posted a 28.9 per cent rise in net profit to Rs 2,155.88 crore from Rs 1,672.33 crore a year earlier.
Nithyananda Reddy, Vice-Chairman and Managing Director of the company, said, “Our (Q2) growth is supported by healthy organic momentum across our key businesses and the successful integration of inorganic opportunities, further strengthening our capabilities and positioning us for the future.
“As we advance our strategic priorities, we remain focused on sustainable growth, financial discipline and creating long-term value for our stakeholders, while continuing to expand access to quality and affordable healthcare worldwide.”
The company has declared an interim dividend of Rs 7 per share.
Shares of the firm ended nearly flat at Rs 1,701.1 apiece, up 0.12 per cent, on the BSE.
(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)
Disclaimer
The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.
More AUROPHARMA News
Open Free Demat Account
₹1,841.70
By signing up I certify terms, conditions & privacy policy
Join Us
Add as preferred source on Google


















